Jane O’Hallahan

1.9k total citations
24 papers, 1.5k citations indexed

About

Jane O’Hallahan is a scholar working on Epidemiology, Microbiology and General Health Professions. According to data from OpenAlex, Jane O’Hallahan has authored 24 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Epidemiology, 21 papers in Microbiology and 2 papers in General Health Professions. Recurrent topics in Jane O’Hallahan's work include Bacterial Infections and Vaccines (21 papers), Pneumonia and Respiratory Infections (18 papers) and Respiratory viral infections research (6 papers). Jane O’Hallahan is often cited by papers focused on Bacterial Infections and Vaccines (21 papers), Pneumonia and Respiratory Infections (18 papers) and Respiratory viral infections research (6 papers). Jane O’Hallahan collaborates with scholars based in New Zealand, Norway and Italy. Jane O’Hallahan's co-authors include Philipp Oster, Diana Martin, Richard Arnold, Diana Lennon, Yvonne Galloway, Johan Holst, Einar Rosenqvist, Kim Mulholland, Anne McNicholas and Concepción Campa Huergo and has published in prestigious journals such as International Journal of Epidemiology, Vaccine and Gynecologic Oncology.

In The Last Decade

Jane O’Hallahan

24 papers receiving 1.4k citations

Peers

Jane O’Hallahan
Johan Holst Norway
G Bjune Norway
Keith Cartwright United Kingdom
Jay Lucidarme United Kingdom
Tessa M. John United Kingdom
Daniela Toneatto Italy
Philipp Oster New Zealand
Lisbeth Meyer Næss Norway
Jenny MacLennan United Kingdom
Jo Anne Welsch United States
Johan Holst Norway
Jane O’Hallahan
Citations per year, relative to Jane O’Hallahan Jane O’Hallahan (= 1×) peers Johan Holst

Countries citing papers authored by Jane O’Hallahan

Since Specialization
Citations

This map shows the geographic impact of Jane O’Hallahan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane O’Hallahan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane O’Hallahan more than expected).

Fields of papers citing papers by Jane O’Hallahan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane O’Hallahan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane O’Hallahan. The network helps show where Jane O’Hallahan may publish in the future.

Co-authorship network of co-authors of Jane O’Hallahan

This figure shows the co-authorship network connecting the top 25 collaborators of Jane O’Hallahan. A scholar is included among the top collaborators of Jane O’Hallahan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane O’Hallahan. Jane O’Hallahan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Holst, Johan, Philipp Oster, Richard Arnold, et al.. (2013). Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): Lessons from past programs and implications for the future. Human Vaccines & Immunotherapeutics. 9(6). 1241–1253. 175 indexed citations
3.
Aspin, Clive, Tanisha Jowsey, Nicholas Glasgow, et al.. (2010). Health policy responses to rising rates of multi‐morbid chronic illness in Australia and New Zealand. Australian and New Zealand Journal of Public Health. 34(4). 386–393. 16 indexed citations
4.
Lennon, Diana, Catherine Jackson, Joanna Stewart, et al.. (2009). Immunogenicity and Tolerability in Infants of a New Zealand Epidemic Strain Meningococcal B Outer Membrane Vesicle Vaccine. The Pediatric Infectious Disease Journal. 28(5). 385–390. 28 indexed citations
5.
Holst, Johan, Diana Martin, Richard Arnold, et al.. (2009). Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine. 27. B3–B12. 310 indexed citations
6.
O’Hallahan, Jane, et al.. (2009). Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease.. PubMed. 122(1291). 48–59. 33 indexed citations
7.
Galloway, Yvonne, et al.. (2008). Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. International Journal of Epidemiology. 38(2). 413–418. 77 indexed citations
8.
McNicholas, Anne, et al.. (2008). Surveillance of vaccine breakthrough cases following MeNZB vaccination.. PubMed. 121(1272). 38–46. 7 indexed citations
9.
Oster, Philipp, Jane O’Hallahan, Ingeborg S. Aaberge, et al.. (2007). Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine. 25(16). 3075–3079. 62 indexed citations
10.
McNicholas, Anne, Yvonne Galloway, Paul A. Stehr‐Green, et al.. (2007). Post-Marketing Safety Monitoring of a New Group B Meningococcal Vaccine in New Zealand, 2004-2006. Human Vaccines. 3(5). 196–204. 28 indexed citations
11.
Nøkleby, Hanne, Preben Aavitsland, Jane O’Hallahan, et al.. (2007). Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine. 25(16). 3080–3084. 69 indexed citations
12.
Hosking, Jamie, Kumanan Rasanathan, Catherine Jackson, et al.. (2007). Immunogenicity, Reactogenicity, and Safety of a P1.7b,4 Strain-Specific Serogroup B Meningococcal Vaccine Given to Preteens. Clinical and Vaccine Immunology. 14(11). 1393–1399. 23 indexed citations
13.
Lennon, Diana, Catherine Jackson, Joanna Stewart, et al.. (2007). New Zealand Epidemic Strain Meningococcal B Outer Membrane Vesicle Vaccine in Children Aged 16–24 Months. The Pediatric Infectious Disease Journal. 26(4). 345–350. 39 indexed citations
14.
Martin, Diana, et al.. (2006). The VR2 Epitope on the PorA P1.7-2,4 Protein Is the Major Target for the Immune Response Elicited by the Strain-Specific Group B Meningococcal Vaccine MeNZB. Clinical and Vaccine Immunology. 13(4). 486–491. 93 indexed citations
15.
Lea, Rod A., et al.. (2006). Understanding the Immune Responses to the Meningococcal Strain-Specific Vaccine MeNZB Measured in Studies of Infants. Clinical and Vaccine Immunology. 13(7). 797–801. 11 indexed citations
16.
Lennon, Diana, Kumanan Rasanathan, Jane O’Hallahan, et al.. (2005). Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: Beginning of epidemic control. Vaccine. 24(9). 1395–1400. 58 indexed citations
17.
18.
O’Hallahan, Jane, Diana Lennon, Philipp Oster, et al.. (2005). From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine. 23(17-18). 2197–2201. 38 indexed citations
19.
Oster, Philipp, Diana Lennon, Jane O’Hallahan, et al.. (2005). MeNZB?: a safe and highly immunogenic tailor-made vaccine against the New Zealand serogroup B disease epidemic strain. Vaccine. 23(17-18). 2191–2196. 224 indexed citations
20.
O’Hallahan, Jane, Diana Lennon, & Philipp Oster. (2004). The Strategy to Control New Zealand's Epidemic of Group B Meningococcal Disease. The Pediatric Infectious Disease Journal. 23(12). S293–S298. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Johan Holst Breakdown of academic impact, for papers by G Bjune Breakdown of academic impact, for papers by Keith Cartwright Breakdown of academic impact, for papers by Jay Lucidarme Breakdown of academic impact, for papers by Tessa M. John Breakdown of academic impact, for papers by Daniela Toneatto Breakdown of academic impact, for papers by Philipp Oster Breakdown of academic impact, for papers by Lisbeth Meyer Næss Breakdown of academic impact, for papers by Jenny MacLennan Breakdown of academic impact, for papers by Jo Anne Welsch
Rankless by CCL
2026